Novartis to acquire Mariana Oncology for up to $1.75 billion

Novartis will acquire Mariana Oncology for $1 billion upfront and up to $750 million in milestone payments. Mariana Oncology develops radiopharmaceuticals for cancer treatment, including lead program MC-339 for small cell lung cancer.

“Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments.”marianaoncology.com

• 1 source
• marianaoncology.comMariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer | NewsMay 2, 2024

Summarized from public sources; check the original articles before acting on it.